This study is in progress, not accepting new patients
Nivolumab and Ipilimumab in Combination With Immunogenic Chemotherapy for Patients With Advanced NSCLC
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at La Jolla, California
- Dates
- study startedestimated completion
- Principal Investigator
- by Hatim Husain
Description
Summary
Official Title
Keywords
Eligibility
Location
Lead Scientist at UCSD
- Hatim Husain
Associate Clinical Professor, Medicine, Vc-health Sciences-schools. Authored (or co-authored) 45 research publications
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Hatim Husain
- ID
- NCT04043195
- Phase
- Phase 1/2 research study
- Study Type
- Interventional
- Participants
- Expecting 30 study participants
- Last Updated